Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression
Canadian Respiratory Journal · 29.11.2023 · 2023 · 1-12
DOI: 10.1155/2023/3291957 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Respiratory Journal, erschienen am 29.11.2023. Verfasst von Hongjuan He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Henan, Zhengzhou 450046, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Asthma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, Henan Youth Talent Support Project, Science and Technology Innovation Talents in Universities of Henan Province.
Abstract (Originalsprache)
Objective
Dysregulation of epithelial-mesenchymal transition (EMT) in the airway epithelium is associated with airway remodeling and the progression of pulmonary fibrosis. Many treatments have been shown to inhibit airway remodeling and pulmonary fibrosis progression in asthma and chronic obstructive pulmonary disease (COPD) by regulating EMT and have few side effects. This review aimed to describe the development of airway remodeling through the EMT pathway, as well as the potential therapeutic targets in these pathways. Furthermore, this study aimed to review the current research on drugs to treat airway remodeling and their effects on the EMT pathway.
Findings
The dysregulation of EMT was associated with airway remodeling in various respiratory diseases. The cytokines released during inflammation may induce EMT and subsequent airway remodeling. Various drugs, including herbal formulations, specific herbal compounds, cytokines, amino acid or protein inhibitors, microRNAs, and vitamins, may suppress airway remodeling by inhibiting EMT-related pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Henan, Zhengzhou 450046, China.
- Department of Otolaryngology, Microbiology and Immunology, New York Medical College, New York, NY 10595, USA.
ORCID-Profile: Xiu-Min Li, Mingsan Miao
Förderung
- Henan Provincial Science and Technology Research Project
- Henan Youth Talent Support Project
- Science and Technology Innovation Talents in Universities of Henan Province
Zitieren
APA
He, H., Ji, X., Cao, L., Wang, Z., Wang, X., Li, X. M., & Miao, M. (2023). Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression. Canadian Respiratory Journal, 2023, 1-12. https://doi.org/10.1155/2023/3291957
Vancouver
He H, Ji X, Cao L, Wang Z, Wang X, Li XM, et al. Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression. Canadian Respiratory Journal. 2023;2023:1-12. doi:10.1155/2023/3291957
BibTeX
@article{He2023,
author = {He, Hongjuan and Ji, Xiaoyan and Cao, Lihua and Wang, Zhenzhen and Wang, Xiaoyu and Li, Xiu-Min and Miao, Mingsan},
title = {Medicine Targeting Epithelial-Mesenchymal Transition to Treat Airway Remodeling and Pulmonary Fibrosis Progression},
journal = {Canadian Respiratory Journal},
year = {2023},
volume = {2023},
pages = {1--12},
doi = {10.1155/2023/3291957}
}
EUVIMED